MA52953A - Compositions et procédés pour la réduction ou le traitement de la résistance à l'insuline et d'états métaboliques - Google Patents

Compositions et procédés pour la réduction ou le traitement de la résistance à l'insuline et d'états métaboliques

Info

Publication number
MA52953A
MA52953A MA052953A MA52953A MA52953A MA 52953 A MA52953 A MA 52953A MA 052953 A MA052953 A MA 052953A MA 52953 A MA52953 A MA 52953A MA 52953 A MA52953 A MA 52953A
Authority
MA
Morocco
Prior art keywords
compositions
reduction
treatment
methods
insulin resistance
Prior art date
Application number
MA052953A
Other languages
English (en)
French (fr)
Inventor
Raffi Afeyan
William Comb
Nadine Daou
Michael Hamill
Chung-Wei Lee
Harry Luithardt
Svetlana Marukian
Original Assignee
Axcella Health Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Axcella Health Inc filed Critical Axcella Health Inc
Publication of MA52953A publication Critical patent/MA52953A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MA052953A 2018-06-20 2019-06-19 Compositions et procédés pour la réduction ou le traitement de la résistance à l'insuline et d'états métaboliques MA52953A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862687727P 2018-06-20 2018-06-20
US201962794134P 2019-01-18 2019-01-18

Publications (1)

Publication Number Publication Date
MA52953A true MA52953A (fr) 2021-04-28

Family

ID=67185732

Family Applications (1)

Application Number Title Priority Date Filing Date
MA052953A MA52953A (fr) 2018-06-20 2019-06-19 Compositions et procédés pour la réduction ou le traitement de la résistance à l'insuline et d'états métaboliques

Country Status (6)

Country Link
US (2) US20210275479A1 (https=)
EP (1) EP3810122A1 (https=)
JP (1) JP2021527671A (https=)
CN (1) CN112689508A (https=)
MA (1) MA52953A (https=)
WO (1) WO2019246299A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20190146A1 (ar) 2016-12-19 2019-06-18 Axcella Health Inc تركيبات حمض أميني وطرق لمعالجة أمراض الكبد
CN112823018A (zh) 2018-06-20 2021-05-18 胺细拉健康公司 制备氨基酸组合物的方法
CN111514276B (zh) * 2020-06-29 2021-07-27 黑龙江中医药大学 短肽Asp-His-Tyr在制备治疗多囊卵巢综合征的药物中的应用
WO2022266480A1 (en) * 2021-06-17 2022-12-22 Axcella Health Inc. Methods of predicting liver fat content and uses thereof
WO2023009444A1 (en) 2021-07-26 2023-02-02 Axcella Health Inc. Amino acid compositions and methods for use in the treatment of post-acute sequelae of covid-19
EP4643658A1 (en) * 2024-04-29 2025-11-05 Laboratorios Ern S.A. Dietary product for hypoproteic diet
CN119679774A (zh) * 2024-11-15 2025-03-25 北京体育大学 预防或治疗代谢性疾病的药物及应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ20022927A3 (cs) * 2000-02-01 2003-06-18 Muscletech Research And Development Inc. Doplňky stravy založené na alfa-lipoové kyselině pro zvýšení čisté svalové hmoty a síly
US20050176827A1 (en) * 2002-05-10 2005-08-11 Lee Steve S. Compositions and methods for glycogen synthesis
CN1557301A (zh) * 2004-01-15 2004-12-29 高春平 降低老年肥胖型糖尿病人血糖和血脂的组合物
US20050233014A1 (en) * 2004-03-02 2005-10-20 Lee Steve S Methods for affecting homeostasis and metabolism in a mammalian body

Also Published As

Publication number Publication date
US20240238232A1 (en) 2024-07-18
US20210275479A1 (en) 2021-09-09
CN112689508A (zh) 2021-04-20
EP3810122A1 (en) 2021-04-28
WO2019246299A1 (en) 2019-12-26
JP2021527671A (ja) 2021-10-14

Similar Documents

Publication Publication Date Title
MA52953A (fr) Compositions et procédés pour la réduction ou le traitement de la résistance à l'insuline et d'états métaboliques
EP3612215A4 (en) COMPOSITIONS AND METHODS OF TREATMENT OF Pneumonia
EP4139348A4 (en) Methods and compositions for treating virus-associated inflammation
EP3720448A4 (en) COMPOSITIONS AND METHODS OF TREATMENT OF MUSCLE ATROPHY AND MYOTONIC DYSTROPHY
EP3341000A4 (en) SYSTEMS AND METHOD FOR TREATING DYSBIOSIS WITH BACTERIAL POPULATIONS FROM FECALIA
MA51796A (fr) Procédés et compositions pour l'administration de protéines thérapeutiques
EP3781214A4 (en) Compositions and methods for treating spinal muscular atrophy
MA52971A (fr) Compositions et procédés pour le traitement de l'infiltration de graisse dans le muscle
MA52961A (fr) Compositions et procédés pour la réduction ou le traitement d'une inflammation
MA50849A (fr) Substances et procédés pour le traitement d'hémoglobinopathies
MA71705A (fr) Substances et procédés pour le traitement d'hémoglobinopathies
EP3846846A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRUS INFECTION
EP3755805A4 (en) COMPOSITIONS AND METHODS FOR TREATMENT OF NON-AGE-RELATED HEARING DAMAGE IN AN INDIVIDUAL
EP3310395A4 (en) RNA-guided transcription regulation and method for the use thereof for the treatment of back pain
EP3390357A4 (en) BIARYL-MONOBACTAM COMPOUNDS AND METHOD FOR THE USE THEREOF FOR THE TREATMENT OF BACTERIAL INFECTIONS
EP3796920A4 (en) TRNA/PRE-MIRNA COMPOSITIONS AND USE IN THE TREATMENT OF CANCER
MA53873A (fr) Compositions et procédés pour le traitement de la presbytie
EP3572050A4 (en) EXCREMENTAL TREATMENT FOR USE IN COLOSTOMIES
EP3448421A4 (en) METHOD AND COMPOSITIONS FOR PREVENTING AND TREATING SURGICAL ADHESIVES
EP3374350A4 (en) HYDROXYPYRIDINONE- AND HYDROXYPYRIMIDINONE-BASED COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS
EP3803403A4 (en) COMPOSITIONS AND METHODS FOR IMAGING
MA51056A (fr) Compositions et méthodes pour le traitement d'affections métaboliques
EP3500278A4 (en) METHOD AND COMPOSITIONS FOR TREATING DISEASES WITH RECOMBINANT SELF-COMPLEMENTARY ADENO-ASSOCIATED VIRUS
EP3655404A4 (en) COMPOUNDS AND THEIR USE TO TREAT MICROBIAL INFECTIONS
MA45226A (fr) Compositions et méthodes de traitement ou de prévention d'affections liées à l'oxalate